Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity. (29th November 2011)

• Record Type: Journal Article
• Authors: El Matri, Leila; Bouraoui, Rym; Chebil, Ahmed; Kort, Fedra; Bouladi, Mejda; Limaiem, Rym; Landoulsi, Hana
• Other Names: Kubota Toshiaki Academic Editor.
• Is Part Of: Journal of ophthalmology. Volume 2012(2012)
• Publication Date: 2011-11-29
• Subjects: Ophthalmology -- Periodicals; Eye Diseases; Ophthalmology; Ophthalmology; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2012/861384
• Languages: English
• ISSNs: 2090-004X

Abstract

Abstract : Purpose . To evaluate functional and anatomic effects of intravitreal bevacizumab in patients with neovascular AMD and initial low visual acuity. Methods . Retrospective case series of 38 eyes with neovascular AMD and initial visual acuity of 20/200 or less, treated with intravitreal bevacizumab injection. Results . Mean followup was 14.1 months ± 7.1 (range: 5 to 24 months). Mean logMAR vision at baseline was 1.38 logMAR ± 0.33, at 6 months was 1.14 logMAR ± 0.37 (P = 0.001 ) and at 12 months was 1.22 logMar ± 0.33 (P = 0.004 ). Mean baseline central retinal thickness was 431 μm ± 159.7 at 6 months was 293.43 μm ± 122.79 (P = 10 - 4 ) and at 12 months was 293.1 μm ± 130 (P = 0.004 ). Visual acuity improved in both patients with or without prior PDT treatment. Conclusions . Intravitreal bevacizumab injection may increase the chance of visual acuity gain in neovascular AMD even in cases with initial low visual acuity.